ATE410162T1 - Verfahren zur herstellung einer fein selbstemulgierbaren pharmazeutischen zusammensetzung - Google Patents

Verfahren zur herstellung einer fein selbstemulgierbaren pharmazeutischen zusammensetzung

Info

Publication number
ATE410162T1
ATE410162T1 AT03719615T AT03719615T ATE410162T1 AT E410162 T1 ATE410162 T1 AT E410162T1 AT 03719615 T AT03719615 T AT 03719615T AT 03719615 T AT03719615 T AT 03719615T AT E410162 T1 ATE410162 T1 AT E410162T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
producing
composition
emulsifiable
Prior art date
Application number
AT03719615T
Other languages
English (en)
Inventor
Ping Gao
Xioarong He
Keith Bolyard
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE410162T1 publication Critical patent/ATE410162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
AT03719615T 2002-04-09 2003-04-07 Verfahren zur herstellung einer fein selbstemulgierbaren pharmazeutischen zusammensetzung ATE410162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37120002P 2002-04-09 2002-04-09

Publications (1)

Publication Number Publication Date
ATE410162T1 true ATE410162T1 (de) 2008-10-15

Family

ID=29250656

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03719615T ATE410162T1 (de) 2002-04-09 2003-04-07 Verfahren zur herstellung einer fein selbstemulgierbaren pharmazeutischen zusammensetzung

Country Status (19)

Country Link
US (1) US20030235596A1 (de)
EP (1) EP1492527B1 (de)
JP (1) JP2005529104A (de)
KR (1) KR100779285B1 (de)
CN (1) CN1305470C (de)
AT (1) ATE410162T1 (de)
AU (1) AU2003223485B2 (de)
BR (1) BR0309138A (de)
CA (1) CA2481677A1 (de)
DE (1) DE60323953D1 (de)
ES (1) ES2310653T3 (de)
HK (1) HK1076382A1 (de)
IL (1) IL164163A0 (de)
MX (1) MXPA04009880A (de)
PL (1) PL372807A1 (de)
RS (1) RS87004A (de)
RU (1) RU2299061C2 (de)
WO (1) WO2003086392A2 (de)
ZA (1) ZA200407711B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10211801B4 (de) 2002-03-16 2004-09-30 Clariant Gmbh Kosmetische und pharmazeutische Zubereitungen enthaltend einen oxalkylierten Polyglycerinester
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
CA2516816C (en) * 2003-02-24 2012-02-07 Pharmaceutical Productions, Inc. Transmucosal drug delivery system
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
JP2006232755A (ja) * 2005-02-25 2006-09-07 Dai Ichi Kogyo Seiyaku Co Ltd 油中水型マイクロエマルション
US8333989B2 (en) * 2005-10-26 2012-12-18 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
CN101351196B (zh) 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
JP5600058B2 (ja) * 2007-04-11 2014-10-01 ファーマシューティカル プロダクションズ， インコーポレイテッド メラトニンタブレットならびに調剤及び使用方法
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
CA2785251A1 (en) * 2009-12-22 2011-06-30 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
AT511045A1 (de) 2011-01-28 2012-08-15 Blum Gmbh Julius Möbelteil mit einer drehmomentübertragenden welle
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103965113A (zh) * 2014-05-06 2014-08-06 四川大学 1-羟乙基-2-取代苯氧甲基苯并咪唑类化合物及其制备方法
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US11400048B2 (en) 2014-06-25 2022-08-02 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
WO2015198350A1 (en) 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
CN117547528A (zh) 2015-05-28 2024-02-13 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN105343002B (zh) * 2015-11-27 2019-07-26 济南康和医药科技有限公司 一种依托考昔口服微乳制剂及其制备方法
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN111729125B (zh) * 2020-07-31 2022-10-04 陕西佰傲再生医学有限公司 骨止血材料
CN114681470A (zh) * 2020-12-28 2022-07-01 雷迪博士实验室有限公司 治疗疼痛的方法
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法
KR102635930B1 (ko) 2021-10-29 2024-02-14 단국대학교 천안캠퍼스 산학협력단 자가나노유화 약물전달시스템을 이용한 셀레콕시브 함유 경구 투여용 제제 및 이의 제조방법
GB2616663A (en) 2022-03-18 2023-09-20 Alkaloid Ad Skopje Pharmaceutical formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2385389A1 (fr) * 1977-03-29 1978-10-27 Capsugel Ag Capsule emboitee remplie d'une matiere visqueuse telle que, notamment, une preparation pharmaceutique liquide
JP2564889B2 (ja) * 1988-03-07 1996-12-18 松下電工株式会社 軸流フアン
US5264223A (en) * 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CN1227003C (zh) * 1998-09-09 2005-11-16 阿尔萨公司 包括液体制剂的剂型
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
TWI232761B (en) * 2000-07-01 2005-05-21 Pharmaceutical Ind Tech & Dev Capsule preparation for oral administration and the preparation method thereof
US20020077328A1 (en) * 2000-07-13 2002-06-20 Fred Hassan Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition

Also Published As

Publication number Publication date
ES2310653T3 (es) 2009-01-16
WO2003086392A2 (en) 2003-10-23
DE60323953D1 (de) 2008-11-20
RU2299061C2 (ru) 2007-05-20
HK1076382A1 (en) 2006-01-20
KR20070014237A (ko) 2007-02-01
BR0309138A (pt) 2005-02-01
IL164163A0 (en) 2005-12-18
RU2004130291A (ru) 2005-05-27
EP1492527A2 (de) 2005-01-05
AU2003223485A1 (en) 2003-10-27
WO2003086392A3 (en) 2004-03-25
RS87004A (en) 2006-12-15
CN1658870A (zh) 2005-08-24
ZA200407711B (en) 2006-06-28
EP1492527B1 (de) 2008-10-08
JP2005529104A (ja) 2005-09-29
MXPA04009880A (es) 2004-12-07
CA2481677A1 (en) 2003-10-23
KR100779285B1 (ko) 2007-11-28
CN1305470C (zh) 2007-03-21
US20030235596A1 (en) 2003-12-25
PL372807A1 (en) 2005-08-08
AU2003223485B2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
ATE410162T1 (de) Verfahren zur herstellung einer fein selbstemulgierbaren pharmazeutischen zusammensetzung
DE69110625D1 (de) Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
ATE128120T1 (de) Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung.
CO5580835A2 (es) Nuevas formulaciones analogas de ciclosporina
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
ATE218359T1 (de) Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
ATE116979T1 (de) 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsäurederivate, salze und ester, verfahren zu ihrer herstellung, pharmazeutische präparate sowie vorprodukte.
ATE386725T1 (de) Heterocyclylverbindungen
ATE137753T1 (de) Codeinsalz einer substituierten carbonsäure, verfahren zu seiner herstellung, seine verwendung und pharmazeutische präparate
EP0366480A3 (de) Verfahren und Mittel zur Behandlung der Alzheimer-Krankheit, verwandter Demenzen und Epilepsie
EP0600395A1 (de) Entzündungshemmendes und analgetisches Diclofenac-Gel
DE69808938T2 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen
DE3878111D1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
DE3573119D1 (en) 8-alkylthio-2-piperazino-pyrimidoû5,4-d¨pyrimidines, their preparation and medicaments containing them
ATE193297T1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE152118T1 (de) Kardioaktive 17b-(3-furyl) und 17b-(4- pyridazinyl)-5beta, 14beta-androstan derivate, verfahren zu ihrer herstellung und pharmazeutische präparate davon
ATE172976T1 (de) 3-aminochroman-spiroderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE25679T1 (de) Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung.
ATE360027T1 (de) 11beta-langkettig-substituierte estratriene, verfahren zur herstellung, pharmazeutische präparate, die diese 11beta-langkettig- substituierten estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
DE50006842D1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
ATE160938T1 (de) Feste orale pharmazeutische zubereitung mit gemfibrozil als aktiver inhaltsstoff und verfahren zur herstellung
DE3881484D1 (de) Optisch aktive produkte von 20,21-dinoreburnamenin-derivaten, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties